These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 20831296)

  • 1. Perspective and desire in comparative effectiveness research: the relative unimportance of mere preferences, the central importance of context.
    Culyer AJ
    Pharmacoeconomics; 2010; 28(10):889-97. PubMed ID: 20831296
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The ISPOR Good Practices for Quality Improvement of Cost-Effectiveness Research Task Force Report.
    McGhan WF; Al M; Doshi JA; Kamae I; Marx SE; Rindress D
    Value Health; 2009; 12(8):1086-99. PubMed ID: 19744291
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Introducing perspectives on comparative effectiveness research.
    Birnbaum HG; Greenberg PE
    Pharmacoeconomics; 2010; 28(10):787-8. PubMed ID: 20831286
    [No Abstract]   [Full Text] [Related]  

  • 4. Investigation of comparative effectiveness research in Asia, Europe, and North America.
    Patel I; Rarus R; Tan X; Lee EK; Guy J; Ahmad A; Chang J
    Indian J Pharmacol; 2015; 47(6):585-93. PubMed ID: 26729947
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Perspectives on comparative effectiveness research: views from diverse constituencies.
    Nellesen D; Birnbaum HG; Greenberg PE
    Pharmacoeconomics; 2010; 28(10):789-98. PubMed ID: 20831287
    [No Abstract]   [Full Text] [Related]  

  • 6. Defining comparative effectiveness research: the importance of getting it right.
    Sox HC
    Med Care; 2010 Jun; 48(6 Suppl):S7-8. PubMed ID: 20473202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Managed care pharmacy sees potential of comparative effectiveness research to improve patient care and lower costs.
    Cahill J; Learner N
    Pharmacoeconomics; 2010; 28(10):931-4. PubMed ID: 20831301
    [No Abstract]   [Full Text] [Related]  

  • 8. EBM, HTA, and CER: clearing the confusion.
    Luce BR; Drummond M; Jönsson B; Neumann PJ; Schwartz JS; Siebert U; Sullivan SD
    Milbank Q; 2010 Jun; 88(2):256-76. PubMed ID: 20579285
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reflections on the ISPOR Special Task Force on U.S. Value Frameworks: Implications of a Health Economics Approach for Managed Care Pharmacy.
    Garrison LP; Neumann PJ; Willke RJ
    J Manag Care Spec Pharm; 2019 Nov; 25(11):1185-1192. PubMed ID: 31663458
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative effectiveness research: Policy context, methods development and research infrastructure.
    Tunis SR; Benner J; McClellan M
    Stat Med; 2010 Aug; 29(19):1963-76. PubMed ID: 20564311
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Translating comparative effectiveness research into clinical practice: the UK experience.
    Walley T
    Drugs; 2012 Jan; 72(2):163-70. PubMed ID: 22268389
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative effectiveness research: decision-based evidence.
    Kowalski CJ; Mrdjenovich AJ
    Perspect Biol Med; 2014; 57(2):224-48. PubMed ID: 25544326
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Maximizing the clinical utility of comparative effectiveness research.
    Umscheid CA
    Clin Pharmacol Ther; 2010 Dec; 88(6):876-9. PubMed ID: 20962776
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Good research practices for measuring drug costs in cost effectiveness analyses: issues and recommendations: the ISPOR Drug Cost Task Force report--Part I.
    Hay JW; Smeeding J; Carroll NV; Drummond M; Garrison LP; Mansley EC; Mullins CD; Mycka JM; Seal B; Shi L
    Value Health; 2010; 13(1):3-7. PubMed ID: 19874571
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An Overview of Value, Perspective, and Decision Context-A Health Economics Approach: An ISPOR Special Task Force Report [2].
    Garrison LP; Pauly MV; Willke RJ; Neumann PJ
    Value Health; 2018 Feb; 21(2):124-130. PubMed ID: 29477389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Uncertainties in real-world decisions on medical technologies.
    Lu CY
    Int J Clin Pract; 2014 Aug; 68(8):936-40. PubMed ID: 25074335
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative effectiveness research and healthcare reform: topics of the day.
    DeKoven M; Goldberg E; Powers J
    Expert Rev Pharmacoecon Outcomes Res; 2011 Aug; 11(4):395-7. PubMed ID: 21831018
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Using cost-effectiveness analysis for formulary decision making: from theory into practice.
    Detsky AS
    Pharmacoeconomics; 1994 Oct; 6(4):281-8. PubMed ID: 10147465
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decision support tools to optimize economic outcomes for type 2 diabetes.
    Shaya FT; Chirikov VV
    Am J Manag Care; 2011 Nov; 17 Suppl 14():S377-83. PubMed ID: 22214425
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integrating economic evaluation methods into clinical and translational science award consortium comparative effectiveness educational goals.
    Iribarne A; Easterwood R; Russo MJ; Wang YC
    Acad Med; 2011 Jun; 86(6):701-5. PubMed ID: 21512372
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.